Galileo, Perlegen Link New Gene Regions to Crohn’s Disease
Galileo Genomics and Perlegen Sciences have wrapped up a linkage disequilibrium-based genome-wide scan of Crohn’s disease in the Quebec founder population, the companies said this week.
The study, which represents the first data resulting from the collaboration between Galileo and Perlegen on 21 diseases, identified two previously reported disease genes, NOD2/CARD15 and OCTN, and “more than 10 new regions strongly associated” with the inflammatory gastrointestinal disorder. Each of these regions contains between one and four genes, Galileo and Perlegen said.
The study was performed on 1,500 individuals using more than 248,000 SNP markers. It brought together Galileo’s gene-discovery software with Perlegen’s high-throughput SNP-genotyping platform and database containing more than 1.5 million validated SNPs.
Over the next two years, the partners plan to apply the linkage disequilibrium-based genome-wide approach to at least 20 additional diseases, according to John Hooper, president and CEO of Galileo Genomics.
Affymetrix to Market NimbleGen’s Microarrays
Affymetrix will commercialize NimbleGen’s customized microarrays, NimbleGen said this week.
Terms of the agreement call for Affy to offer its customers made-to-order versions of the NimbleExpress array for use on the Affymetrix GeneChip systems. Customers will be required to place a minimum order of 10 arrays, and there will be a four-week lead time on orders, NimbleGen said.
The NimbleExpress array is made using maskless photolithography, enabling greater flexibility in design than the photolithography masks on traditional Affymetrix arrays.
Cellomics Licenses High-Content Screening Patents to GE Healthcare
Cellomics has non-exclusively licensed its high-content screening patents to GE Healthcare, and will allow the giant conglomerate to sublicense these patent rights to pharmaceutical companies, the companies said this week.
Cellomics, of Pittsburgh, Pa., said it has more than 30 issued or allowed patents and an additional 30 patents pending in high content screening, a type of cellular assay it invented and defined.
Affymetrix, Immusol Partner On Cancer Drug Discovery
Immusol and Affymetrix have signed onto a scientific collaboration in which Immusol will use Affymetrix’s gene chips in cancer drug discovery, the companies said this week.
Terms of the collaboration call for San Diego-based Immusol to use Affymetrix’s microarrays to conduct gene expression-profiling on its engineered tumor cells, and identify pathways related to cancer. The program also aims to “acquire and validate additional therapeutic target candidates,” the parties said.
The companies’ scientists plan to obtain information about the molecular mechanism of actions of drugs or drug targets through perturbing the system and observing the results.
Paradigm Genetics Awarded $742,000 SBIR Grant for Liver Metabolomics
Paradigm Genetics has received a $742,000 phase I/II SBIR contract from the National Institute of Environmental Health Sciences for an effort to use metabolomics to discover biochemical pathways of drug-induced liver injury, the company said last week.
The contract, “Metabolomics and Pathway Linkage: Urine, Serum, and Liver,” includes $99,000 in funding for phase I, which is expected to run for six months; and $643,000 for phase II, which is expected to run for two more years and will be awarded upon the completion of phase I.
Under the contract, Paradigm will use mass spectrometry to conduct pre-clinical studies on three compounds known to cause liver damage, and will profile hundreds of small molecular weight biochemicals with a potential link to liver toxicity.
PamGene and Jerini Peptide Technologies Offer Products
PamGene International and Jerini Peptide Technologies will jointly offer their microarray and peptide products for kinase studies, the companies announced this week.
Under the agreement, PamGene and Jerini will offer PamGene’s 96-well microarray platform and Jerini’s kinase peptide substrates.
Jerini Peptide Technologies of Berlin, a division of Jerini, provides peptide-based services and products. PamGene International, based in the Netherlands, offers three-dimensional microarray technology.